Terms: = Prostate cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Staging
322 results:
1. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
2. Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
Kolade OU; Brink A; Ayeni AO; More S; Holness J
Cancer Imaging; 2024 Apr; 24(1):46. PubMed ID: 38556864
[TBL] [Abstract] [Full Text] [Related]
3. [
Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
[TBL] [Abstract] [Full Text] [Related]
4. Predictive accuracy of boosted regression model in estimating risk of venous thromboembolism following minimally invasive radical surgery in pharmacological prophylaxis-naïve men with prostate cancer.
Leong CH; Ranjan SR; Javed A; Alsaedi BSO; Nabi G
World J Surg Oncol; 2024 Feb; 22(1):67. PubMed ID: 38395873
[TBL] [Abstract] [Full Text] [Related]
5. Role of non-contrast CT component of prostate-specific membrane antigen PET/CT scan in the detection of peripheral zone prostate cancer.
Aggarwal P; Krishna Kumar RG; Das CJ; Kubihal V; Subudhi TK; Khan MA; Kumar R
Br J Radiol; 2024 Jan; 97(1153):195-200. PubMed ID: 38263835
[TBL] [Abstract] [Full Text] [Related]
6. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer.
Madendere S; Kılıç M; Köseoğlu E; Aykanat İC; Eden AB; Coşkun B; Tekkalan FB; Balbay MD
Urol Oncol; 2024 Feb; 42(2):29.e9-29.e15. PubMed ID: 38114351
[TBL] [Abstract] [Full Text] [Related]
7. Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?
Belue MJ; Blake Z; Yilmaz EC; Lin Y; Harmon SA; Nemirovsky DR; Enders JJ; Kenigsberg AP; Mendhiratta N; Rothberg M; Toubaji A; Merino MJ; Gurram S; Wood BJ; Choyke PL; Turkbey B; Pinto PA
Prostate; 2023 Dec; 83(16):1519-1528. PubMed ID: 37622756
[TBL] [Abstract] [Full Text] [Related]
8. The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis.
Gossili F; Mogensen AW; Konnerup TC; Bouchelouche K; Alberts I; Afshar-Oromieh A; Zacho HD
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):281-294. PubMed ID: 37597010
[TBL] [Abstract] [Full Text] [Related]
9. Targeted Biopsy in Men High Risk for prostate cancer:
Pepe P; Pennisi M
Clin Genitourin Cancer; 2023 Dec; 21(6):639-642. PubMed ID: 37394379
[TBL] [Abstract] [Full Text] [Related]
10. Development and external validation of a multivariable [
Muehlematter UJ; Schweiger L; Ferraro DA; Hermanns T; Maurer T; Heck MM; Rupp NJ; Eiber M; Rauscher I; Burger IA
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3137-3146. PubMed ID: 37261472
[TBL] [Abstract] [Full Text] [Related]
11. Head-to-Head Comparison of
Exterkate L; Hermsen R; Küsters-Vandevelde HVN; Prette JF; Baas DJH; Somford DM; van Basten JA
Eur Urol Oncol; 2023 Dec; 6(6):574-581. PubMed ID: 37230883
[TBL] [Abstract] [Full Text] [Related]
12. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
Du X; Dong Y; Liu J; Su Y; Zhu Y; Pan J; Dong B; Chen R; Liu J; Tong Z; Pienta KJ; Rowe SP; Dong L; Xue W
Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552
[TBL] [Abstract] [Full Text] [Related]
13. Prior MRI-imaging impact of patients submitted to brachytherapy for prostate cancer.
Vieira E Brito D; Fereira A; Pereira J; Pereira-Lourenço M; Godinho R; Pereira B; Peralta P; Conceiçao P; Reis Mario A; Paula Rabaça C
Actas Urol Esp (Engl Ed); 2023 Oct; 47(8):503-508. PubMed ID: 37086843
[TBL] [Abstract] [Full Text] [Related]
14. Negative predictive value of PSMA PET scan for lymph node staging in patients undergoing robotic radical prostatectomy and pelvic lymph node dissection.
Adiyat KT; Pooleri GK; Cherian DT; Santhamma SGN; Ravichandran K; Sundaram S
Int Urol Nephrol; 2023 Jun; 55(6):1453-1457. PubMed ID: 37086333
[TBL] [Abstract] [Full Text] [Related]
15. Multi-Institutional Clinical Outcomes of Biopsy Gleason Grade Group 5 prostate cancers Treated With Contemporary High-Dose Radiation and Long-Term Androgen Deprivation Therapy.
Chilukuri S; Mallick I; Agrawal A; Maitre P; Arunsingh M; James FV; Kataria T; Narang K; Gurram BC; Anand AK; Utreja N; Dutta D; Pavamani S; Mitra S; Mallik S; Mahale N; Chandra M; Chinnachamy AN; Shahid T; Raghunathan MS; Kannan V; Mohanty SK; Basu T; Hotwani C; Panigrahi G; Murthy V
Clin Oncol (R Coll Radiol); 2023 Jul; 35(7):454-462. PubMed ID: 37061457
[TBL] [Abstract] [Full Text] [Related]
16. A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients.
Wit EMK; KleinJan GH; Berrens AC; van Vliet R; van Leeuwen PJ; Buckle T; Donswijk ML; Bekers EM; van Leeuwen FWB; van der Poel HG
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2861-2871. PubMed ID: 37036490
[TBL] [Abstract] [Full Text] [Related]
17. Histopathologically Validated Diagnostic Accuracy of PSMA-PET/CT in the Primary and Secondary staging of prostate cancer and the Impact of PSMA-PET/CT on Clinical Management: A Systematic Review and Meta-analysis.
Jeet V; Parkinson B; Song R; Sharma R; Hoyle M
Semin Nucl Med; 2023 Sep; 53(5):706-718. PubMed ID: 37005145
[TBL] [Abstract] [Full Text] [Related]
18. [
Vats K; Chakraborty A; Rakshit S; Damle A; Sarma HD; Satpati D
Nucl Med Biol; 2023; 118-119():108331. PubMed ID: 36933456
[TBL] [Abstract] [Full Text] [Related]
19. The Changing Face of cN0M0 prostate cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management.
Sacco M; Gandaglia G; Aas K; Ceci F; Chiu P; Fankhauser CD; Fournier G; Heiddeger I; Kasivisvanathan V; Kesch C; Maggi M; Martini A; Olivier J; Ploussard G; Preisser F; Puche-Sanz I; Rajwa P; Soeterik T; Thibault C; Valerio M; van den Bergh RCN; Zattoni F; Rivas JG; Moschini M; Gillessen S; Bossi A; Gontero P; Marra G;
Clin Genitourin Cancer; 2023 Jun; 21(3):416.e1-416.e10. PubMed ID: 36609130
[TBL] [Abstract] [Full Text] [Related]
20. Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer.
Rajwa P; Pfister D; Rieger C; Heidenreich J; Drzezga A; Persigehl T; Shariat SF; Heidenreich A
Prostate; 2023 Mar; 83(4):385-391. PubMed ID: 36564936
[TBL] [Abstract] [Full Text] [Related]
[Next]
